Current and emerging therapies in multiple sclerosis

A systematic review

Wanda Castro-Borrero, Donna Graves, Teresa C. Frohman, Angela Bates Flores, Paula Hardeman, Diana Logan, Megan Orchard, Benjamin Greenberg, Elliot Frohman

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.

Original languageEnglish (US)
Pages (from-to)205-220
Number of pages16
JournalTherapeutic Advances in Neurological Disorders
Volume5
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Multiple Sclerosis
Off-Label Use
Relapsing-Remitting Multiple Sclerosis
United States Food and Drug Administration
Therapeutics
Autoimmune Diseases
Young Adult
Safety
Drug Therapy
Pharmaceutical Preparations

Keywords

  • disease-modifying therapies
  • emerging therapies
  • fingolimod
  • glatiramer acetate
  • interferon β
  • multiple sclerosis
  • natalizumab

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pharmacology

Cite this

Current and emerging therapies in multiple sclerosis : A systematic review. / Castro-Borrero, Wanda; Graves, Donna; Frohman, Teresa C.; Flores, Angela Bates; Hardeman, Paula; Logan, Diana; Orchard, Megan; Greenberg, Benjamin; Frohman, Elliot.

In: Therapeutic Advances in Neurological Disorders, Vol. 5, No. 4, 07.2012, p. 205-220.

Research output: Contribution to journalArticle

Castro-Borrero, W, Graves, D, Frohman, TC, Flores, AB, Hardeman, P, Logan, D, Orchard, M, Greenberg, B & Frohman, E 2012, 'Current and emerging therapies in multiple sclerosis: A systematic review', Therapeutic Advances in Neurological Disorders, vol. 5, no. 4, pp. 205-220. https://doi.org/10.1177/1756285612450936
Castro-Borrero, Wanda ; Graves, Donna ; Frohman, Teresa C. ; Flores, Angela Bates ; Hardeman, Paula ; Logan, Diana ; Orchard, Megan ; Greenberg, Benjamin ; Frohman, Elliot. / Current and emerging therapies in multiple sclerosis : A systematic review. In: Therapeutic Advances in Neurological Disorders. 2012 ; Vol. 5, No. 4. pp. 205-220.
@article{41372dde49ca4c11abe849ac8315ad28,
title = "Current and emerging therapies in multiple sclerosis: A systematic review",
abstract = "Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.",
keywords = "disease-modifying therapies, emerging therapies, fingolimod, glatiramer acetate, interferon β, multiple sclerosis, natalizumab",
author = "Wanda Castro-Borrero and Donna Graves and Frohman, {Teresa C.} and Flores, {Angela Bates} and Paula Hardeman and Diana Logan and Megan Orchard and Benjamin Greenberg and Elliot Frohman",
year = "2012",
month = "7",
doi = "10.1177/1756285612450936",
language = "English (US)",
volume = "5",
pages = "205--220",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Current and emerging therapies in multiple sclerosis

T2 - A systematic review

AU - Castro-Borrero, Wanda

AU - Graves, Donna

AU - Frohman, Teresa C.

AU - Flores, Angela Bates

AU - Hardeman, Paula

AU - Logan, Diana

AU - Orchard, Megan

AU - Greenberg, Benjamin

AU - Frohman, Elliot

PY - 2012/7

Y1 - 2012/7

N2 - Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.

AB - Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.

KW - disease-modifying therapies

KW - emerging therapies

KW - fingolimod

KW - glatiramer acetate

KW - interferon β

KW - multiple sclerosis

KW - natalizumab

UR - http://www.scopus.com/inward/record.url?scp=84863580562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863580562&partnerID=8YFLogxK

U2 - 10.1177/1756285612450936

DO - 10.1177/1756285612450936

M3 - Article

VL - 5

SP - 205

EP - 220

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

IS - 4

ER -